- Home
- DOUG vs OBIO Comparison
DOUG vs OBIO Comparison
Compare DOUG & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | OBIO |
|---|---|---|
| Founded | 1911 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.5M | 246.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DOUG | OBIO |
|---|---|---|
| Price | $1.85 | $4.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | ★ 670.5K | 143.8K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | 33.13 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $955,578,000.00 | $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | $10.41 | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $1.51 | $2.20 |
| 52 Week High | $3.20 | $5.42 |
Technical Indicators
Market Signals| Indicator | DOUG | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 56.47 |
| Support Level | $1.55 | $4.02 |
| Resistance Level | $2.87 | $4.88 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 87.70 | 76.47 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.